retatrutide telegram Demand for Unapproved Weight-Loss Drug Surges on Social Media Vial of unapproved peptide retatrutide

doi: 10.3390/ijms232314631, Summary Keywords GLP-1/GIP dual agonist, metabolic regulation, obesity, obstructive sleep apnea, tirzepatide Citation Fang Q, Zhu Y, Rao M and Liu P (2026) GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives

Henry uses compounding pharmacies subject to FDA regulations to make these drugs, though it's worth noting that the actual substances that leave a compounding pharmacy are not FDA-approved, as they contain certain nuances of their formulations (typically inactive ingredients) that differentiate them from approved, brand-name drugs

Need the standalone version

Compounded medications discussed in this article are not FDA-approved finished drug products and are not reviewed by FDA for safety, effectiveness, or quality before marketing

Will Pills Mean Fewer Shortages Than Injectable GLP-1s

If you accidentally leave a reconstituted vial out overnight, it may still be usable, but potency loss is almost certain